| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | Intracellular drug delivery : potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy |
| Autor/-in: | Luginbühl, Vera Meier, Nicolas Kovar, Karin Rohrer, Jack |
| DOI: | 10.1016/j.biotechadv.2018.02.005 |
| Erschienen in: | Biotechnology Advances |
| Band(Heft): | 36 |
| Heft: | 3 |
| Seite(n): | 613 |
| Seiten bis: | 623 |
| Erscheinungsdatum: | Mai-2018 |
| Verlag / Hrsg. Institution: | Elsevier |
| ISSN: | 0734-9750 1873-1899 |
| Sprache: | Englisch |
| Schlagwörter: | Antibody-drug conjugates; Biotechnological production; Cancer targeting; Intracellular delivery; Receptor-mediated endocytosis; Shiga toxin; Shiga toxin subunit B; Toxin-drug conjugates |
| Fachgebiet (DDC): | 572: Biochemie 610: Medizin und Gesundheit 660.6: Biotechnologie |
| Zusammenfassung: | A treasure trove of intracellular cancer drug targets remains hidden behind cell membranes. However, engineered pathogen-derived toxins such as Shiga toxins can deliver small or macromolecular drugs to specific intracellular organelles. After binding to ganglioglobotriaosylceramide (Gb3, CD77), the non-toxic subunit B (StxB) of the Shiga-holotoxin is endocytosed and delivers its payload by a unique retrograde trafficking pathway via the endoplasmic reticulum to the cytosol. This review provides an overview of biomedical applications of StxB-based drug delivery systems in targeted cancer diagnosis and therapy. Biotechnological production of the Stx-material is discussed from the perspective of developing efficacious and safe therapeutics. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/11523 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Lizenz gemäss Verlagsvertrag |
| Departement: | Life Sciences und Facility Management |
| Organisationseinheit: | Institut für Chemie und Biotechnologie (ICBT) |
| Enthalten in den Sammlungen: | Publikationen Life Sciences und Facility Management |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Luginbühl, V., Meier, N., Kovar, K., & Rohrer, J. (2018). Intracellular drug delivery : potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy. Biotechnology Advances, 36(3), 613–623. https://doi.org/10.1016/j.biotechadv.2018.02.005
Luginbühl, V. et al. (2018) ‘Intracellular drug delivery : potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy’, Biotechnology Advances, 36(3), pp. 613–623. Available at: https://doi.org/10.1016/j.biotechadv.2018.02.005.
V. Luginbühl, N. Meier, K. Kovar, and J. Rohrer, “Intracellular drug delivery : potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy,” Biotechnology Advances, vol. 36, no. 3, pp. 613–623, May 2018, doi: 10.1016/j.biotechadv.2018.02.005.
LUGINBÜHL, Vera, Nicolas MEIER, Karin KOVAR und Jack ROHRER, 2018. Intracellular drug delivery : potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy. Biotechnology Advances. Mai 2018. Bd. 36, Nr. 3, S. 613–623. DOI 10.1016/j.biotechadv.2018.02.005
Luginbühl, Vera, Nicolas Meier, Karin Kovar, and Jack Rohrer. 2018. “Intracellular Drug Delivery : Potential Usefulness of Engineered Shiga Toxin Subunit B for Targeted Cancer Therapy.” Biotechnology Advances 36 (3): 613–23. https://doi.org/10.1016/j.biotechadv.2018.02.005.
Luginbühl, Vera, et al. “Intracellular Drug Delivery : Potential Usefulness of Engineered Shiga Toxin Subunit B for Targeted Cancer Therapy.” Biotechnology Advances, vol. 36, no. 3, May 2018, pp. 613–23, https://doi.org/10.1016/j.biotechadv.2018.02.005.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.